Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Income from Continuing Operations (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Income from Continuing Operations for 16 consecutive years, with 163400000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 68.83% to 163400000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 137030000.0 through Dec 2025, down 39.63% year-over-year, with the annual reading at 137130000.0 for FY2025, 39.7% down from the prior year.
  • Income from Continuing Operations hit 163400000.0 in Q4 2025 for Ironwood Pharmaceuticals, down from 40120000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 391272000.0 in Q2 2021 to a low of 1089478000.0 in Q2 2023.
  • Historically, Income from Continuing Operations has averaged 24872900.0 across 5 years, with a median of 30353500.0 in 2022.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 5462.3% in 2024 and later skyrocketed 2846.74% in 2025.
  • Year by year, Income from Continuing Operations stood at 41355000.0 in 2021, then skyrocketed by 177.23% to 114647000.0 in 2022, then crashed by 101.52% to 1740000.0 in 2023, then tumbled by 5462.3% to 96784000.0 in 2024, then plummeted by 68.83% to 163400000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for IRWD at 163400000.0 in Q4 2025, 40120000.0 in Q3 2025, and 23622000.0 in Q2 2025.